To assess the feasibility of treatments for patients with small cell lung cancer (SCLQ showing a poor performance status (PS, Eastern Cooperative Oncology Group; ECOG 3 or 4), we retrospectively reviewed the outcome for 13 SCLC patients showing poor PS treated at the National Cancer Center Hospital between January 1984 and May 1994. The main factors which contributed to poor prognosis were superior vena cava (SVC) syndrome, massive pleural effusion, tracheal stenosis due to lymph node swelling, pericardial effusion and pulmonary fibrosis (causing dyspnea in combination), brain metastasis resulting in neurological disturbance, cachexia, Eaton-Lambert syndrome causing muscle weakness, retroperitoneal lymph node metastasis causing abdominal pain, peritoneal effusion due to abdominal lymph node swelling, vertebral metastasis causing paraplegia, and dermatomyositis/polymyositis (DM/PM) causing muscle weakness. All of the patients received chemotherapy with or without radiotherapy. The PS of 8 patients improved with treatment, but no improvement was seen in 5. W e analyzed these 13 patients and considered the treatments for those with poor PS. Chemo-radiotherapy was tolerable in SCLC patients showing PS 3, and improved their PS if severe conditions or combined disease did not arise concurrently. It was further suggested that PS 4 patients with severe conditions or combined disease should not be given the treatments. (Jpn J Clin Oncol 26: 128-133, 1996) 
Introduction
Over the past decade there has been a modest improvement in the survival of patients with small cell lung cancer (SCLC), although there are few long-term survivors. Although the rate of response to combination chemotherapy is 85-95% in limitedstage disease (LD) and 65-85% in extensive-stage disease (ED), 0 the respective long-term survival rates are only 15% and 0-5%. SCLC is rarely treated by surgery, since it is chemo-and radiosensitive. Therefore chemotherapy and/or radiotherapy is usually the initial treatment of choice.
Poor performance status (PS) has been reported to be a risk factor for chemoradiotherapy in Received: June 16, 1995 Accepted: November 14, 1996 For reprints and all correspondence: Nagahiro Saijo, Division of Pharmacology, National Cancer Center Research Institute, 1-1, Tsukiji 5-chome, Chuo-ku, Tokyo 104 patients with SCLC, 2 ^ and those showing a good PS are eligible for clinical trials. However, because many patients show a rapid deterioration in PS with tumor progression, we need to consider the initial treatment strategies for patients with poor PS. Few reports have addressed the causes of poor PS and the efficacy of chemoradiotherapy in such patients. In the present study, we retrospectively analyzed the characteristics of 13 SCLC patients showing poor PS who had received chemotherapy and/or radiotherapy, and here we discuss the implications of intensive treatment for this group.
Patients and Methods
We reviewed the medical charts of patients who were diagnosed as having SCLC cytologically or histologically and treated between January 1984 and May 1994 at the National Cancer Center Hospital (NCCH), Tokyo. Poor performance status included a pretreatment Eastern Cooperative Oncology Group (ECOG) PS score of 3-4. Patients were checked for age, sex, stage, and PS before the treatments, and PS was also checked after treatments. We analyzed the factors associated with poor PS, the treatment regimens that were used as induction therapy, the effects of the treatments, hematological toxicities, modalities of supportive care such as O2 supply, administration of antibiotics, blood transfusion and patient survival times. Limited disease was defined as evidence of disease within 1 hemithorax and supraclavicular fossa and extensive disease as evidence of disease beyond these borders. The extent of disease was assessed on the basis of findings at physical examination, biochemical profile, chest x-ray, chest tomography and computed tomography (CT), head CT or magnetic resonance imaging (MRI) scan, abdominal echography or abdominal CT scan, bronchofiberscopy and bone marrow examination. We then retrospectively analyzed the characteristics of SCLC patients with poor PS.
Results

Patient Profiles
Between January 1984 and May 1994 at the NCCH, 269 patients were cytologically or histologically diagnosed as having SCLC and then treated. They comprised 33 patients (12%) with PS 0, 181 (67%) with PS 1, 40 (15%) with PS 2, 10 (3.7%) with PS 3 and 5 (1.9%) with PS 4. Thirteen of these patients (4.8%) met the criteria for untreated disease and a pretreatment PS score of 3-4 (ECOG).
The characteristics of the 13 patients were: mean age 65.6 (range 42-79) yr, male: female ratio 9:4, 8 patients had PS 3 and 5 PS 4, 5 patients had limited disease (LD) and 8 extensive disease (ED). Weight loss of over 15% (cachexia) in the 2-3 months before treatment was observed in two patients.
Chemotherapy Treatment Regimens
The treatment regimens were seven courses of PVP: cisplatin (CDDP) 80 mg/m 2 4 ; one course of l-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chlorethy)-3-nitrosourea hydrochloride (ACNU) 140 mg/body + CPA 1000 mg/body + VCR 3 mg/ body to patient No. 9. Patients Nos. 5 and 7 received two and four courses of the PVP/CAV regimen, respectively.
Causes of Poor PS
The factors associated with a poor PS were superior vena cava (SVC) syndrome in 5 patients, massive pleural effusion (requiring drainage to relieve dyspnea) in 3, tracheal stenosis due to lymph node swelling in 1, pulmonary fibrosis in 1, and pericardial effusion in 1 (dyspnea caused by various combinations of these five factors), brain metastasis causing neurological disturbance in 3, cachexia in 2, Eaton-Lambert syndrome causing muscle weakness in 1, retroperitoneal lymph node metastasis causing abdominal pain in 1, peritoneal effusion due to abdominal lymph node swelling in 1, vertebral metastasis causing paraplegia in 1, and dermatomyositis/polymyositis (DM/PM) causing muscle weakness in 1. Six of the 13 patients had a combination of the above conditions, resulting in poor PS (Tables I, II) . During the same period, 17 patients (6.3%) with SVC syndrome, 18 (6.7%) with massive pleural effusion and 29 (11%) with brain metastasis before initial treatment at our institute were recognized among all 269 patients for whom medical charts were available.
Treatments and Outcome
As induction therapy, 33 courses of chemotherapy were given to 13 patients, and 5 patients were given radiotherapy. Pleural drainage and pericardial drainage were given to 3 and 1 patient respectively to reduce their dyspnea. Three patients received whole-brain irradiation (WBI) for brain metastasis; in 2 of them, this was an initial therapy to relieve severe neurological disorders (left hemiplegia and motor disturbance, respectively). Two patients were given thoracic radiotherapy for SVC syndrome as an initial therapy.
Overall, 3 (23%) patients achieved complete remission and 5 (38%) partial remission. The overall response rate was 8/13 (62%). Two patients died within one month (treatment-related death; Table III shows a comparison of stage, response and mean survival time between these two groups. Although the distribution of the stages was balanced, patients who responded well tended to have a good PS and long survival.
Analysis of the Patients
The characteristics of the patients (Nos. 1, 2, 3 and 6) with improved PS are shown in Table I . These patients had SVC syndrome and/or massive pleural effusion. In two of them (Nos. 2 and 6) who had massive ipsilateral pleural effusion, pleural drainage was initiated because of respiratory distress. Patient No. 3 did not require drainage initially, but received pericardial drainage because of cardiac failure and an increase of pericardial effusion after the first course of chemotherapy. Eventually, the cardiac failure was resolved and the patient continued to receive chemotherapy. Recovery of arterial blood gas values was seen in these patients: the mean partial pressure of oxygen recovered from 62 mmHg (range 58-69) before the treatment to 82 mmHg (range 72-89) after the induction therapies.
In two patients (Nos. 4 and 5), brain metastasis was well controlled by combined chemoradiotherapy. Patient No. 7 who had abdominal pain due to retroperitoneal lymph node metastasis showed an improved PS score after chemotherapy. Patient No. 8 complained of muscle weakness due to Eaton-Lambert syndrome, but responded well to chemotherapy with recovery of muscle power. These effects began to appear at 19.1 days after the start of treatment (range, 10 to 44 days). Table II shows the five patients with nonimproved PS. Two (Nos. 9 and 10) of them had other combined diseases, including muscle weakness due to dermatomyositis/polymyositis (DM/PM) (No. 9), and dyspnea due to pulmonary fibrosis (No. 10). Patient No. 9 with DM/PM required steroid hormone (methylprednisolone 1000 mg/day x8) to control this severe disease, and died within one month (TRD) because of sepsis due to candidiasis. Patient No. 10 with severe pulmonary fibrosis did not respond to the treatments^and finally died of pneumonia. Of the other three patients, No. 11 did not show improvement of PS due to treatment-resistant brain metastasis. Patient No. 12, who had muscle weakness of the lower extremities due to cachexia, received one course of chemotherapy, after which the disease progressed, and she died of pneumonia. Patient No. 13, who had massive pleural effusion, hemiplegia due to vertebral metastasis and cachexia, did not respond to the treatments, showed deterioration of PS and died of sepsis (TRD). This patient also had bone marrow involvement.
Hematological Toxicities and Supportive Care
The frequency of adverse effects was compared between patients with improved and non-improved PS (Table IV) . A total of 19 courses of antibiotic treatments were required: 12 out of 25 courses for patients with improved PS, and 7 out of 8 courses for patients with non-improved PS.
Five out of a total of 33 courses induced hemoglobin anemia<8.0g/dl. The mean number of units of concentrated red cell (CRC) transfusions required per chemotherapy course averaged 1.1 and 2.0 IU in patients with non-improved and improve PS, respectively. Thrombocytopenia (platelet<5.0x occurred in seven of the 33 courses: four out of eight courses for non-improved patients and three out of 25 courses for improved patients. The mean numbers of units of platelet transfusion required per course were 2.8 and 6.4 IU for nonimproved and improved patients, respectively. Eleven out of 13 patients required oxygen (O2). All 5 patients with non-improved PS required O2, the mean duration of O2 supply being 48.4 days (range, 1 to 167 days). Two treatment-related deaths were included in this group of patients. Six patients out of eight with improved PS required 02 and the mean duration of O2 administration was 18.8 days (range, 0 to 64 days).
Discussion
Performance status is one of the most important prognostic factors in SCLC.
4>6) It has been reported that poor initial PS is an adverse prognostic factor, 2 '^ although few reports have addressed the causes of poor PS and the effects of treatment on such patients. In the present study we retrospectively analyzed the causes of poor PS in SCLC patients, and the effects of treatment.
The PS of patients was improved after treatment if their PS deteriorated due to factors mainly caused by SVC syndrome, massive pleural effusion, stenosis of the main respiratory tract and brain metastasis. An excellent response rate (7/8 cases: 88%) and a longer mean survival time (11.8 months) in the improved PS group were observed in comparison with the non-improved PS group. SCLC frequently involves the mediastinal lymph nodes, thus compressing important organs located in the mediastinum, such as the superior vena cava, trachea, bronchi and pulmonary artery, and progression is rapid. This compression can be relieved by chemotherapy and/or radiotherapy and can improve the circulation and stenosis of the" air tracts. Ashokakumal et al. reported that SVC syndrome due to SCLC could result from a small tumor and did not necessarily indicate a poor prognosis. 8 ' However, as SVC syndrome is classified as an oncologic emergency, 9 ' it is necessary to evaluate such cases quickly, and treatment should be started as soon as possible for this chemoradiosensitive tumor.
Patients with non-improved PS responded poorly to treatment: only one PR was observed among the 5 cases, the response rate was 20% and the mean suvival time was 2.6 months. It is natural that a better response rate and longer survival time were observed in the improved PS group than in the non-improved PS group, because we essentially compared response rate and survival between PS 3 patients and PS 4 patients. The poor PS of these patients was due mainly to severe conditions due to SCLC itself, such as cachexia and vertebral metastasis, or other severe combined diseases such as dermatomyositis/polymyositis and pulmonary fibrosis. Therefore it is suggested that patients with such severe conditions or combined disease should not be given chemotherapy, and that patients without them may be candidates for chemotherapy and radiotherapy. However, in order to confirm thtis, we need to conduct a randomized trial.
The present study included 3 patients with brain metastasis, 2 of whom had an improved PS whereas 1 did not. Kristjansen et al. studied 21 patients who had initial brain metastases, including 14 patients who had a WHO performance status of 3-4. Eight of these patients died within 4 weeks, suggesting that PS at the time of diagnosis was an extremely important prognostic factor.
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' Further analysis of more patients with brain metastasis and poor PS is thus needed.
In summary, chemoradiotherapy was tolerable in SCLC patients with PS 3 and led to improvement if severe conditions or combined disease did not arise concurrently. It is further suggested that patients with PS 4 showing severe conditions or combined disease should not be given these treatments.
